Europe Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care remain patchy across Europe, and survivors can face life-altering side effects that surface decades after treatment ends. Carina Schneider and…
Korea Vaxcellbio aims to become a genuine game changer in the global immune cell therapy market Dr Je-Jung Lee, CEO of Vaxcellbio, discusses how his experience as a physician and immunotherapy researcher shaped the company’s patient-centred mission. He outlines Vaxcellbio’s differentiated NK cell, CAR-T and CAR-MIL platforms, manufacturing strategy, Korea’s evolving…
Saudi Arabia Mostafa Abdelrahman, General Manager of Lilly Saudi Arabia, discusses the company’s evolution from medicine supplier to healthcare partner, supporting Vision 2030 through innovation, public-private collaboration and localisation. He highlights advances in obesity, Alzheimer’s disease and oncology, alongside technology transfer, clinical research and talent development, while outlining priorities to expand patient…
Korea Our mission has remained constant: to develop and provide cancer patients with precise treatment and early detection, and to improve patient outcomes Dr. Tae-You Kim, CEO and Co-Founder of IMBdx, discusses the company’s liquid biopsy technology, AI-driven genomic analysis and ambition to build a global precision oncology platform. He outlines…
Taiwan Taiwan’s investment culture remains heavily oriented toward semiconductors and electronics, and few investors are yet convinced to commit capital to biotech Dr. Lin, Founder and Chief Scientific Officer of Tripartite Therapeutics, discusses the inspiration behind the company’s ADC platform of OmniLink® and Polarpeutic® technologies, designed to overcome key limitations in…
UK Seven months into the job as CEO of GSK, Luke Miels has moved faster and bigger than most expected. Having laid out an M&A strategy based around small bolt-ons at the start of the year, Miels then ripped up his own rule book with the USD 10.6 billion acquisition of…
USA Mohit Manrao, SVP and Head of US Oncology at AstraZeneca, leads the company’s effort to drive impact for cancer patients across the US. He elaborates on what it means to realise AstraZeneca’s bold ambition to eliminate cancer as a cause of death and shares how this mission goes beyond developing…
Korea Professor Do-Youn Oh discusses advances in gastrointestinal oncology, reflecting on the practice-changing TOPAZ-1 trial, Korea’s strengths in clinical research, and the importance of biomarker-driven therapies. She shares her approach to investigator-led drug development, industry collaboration, and translational research, while outlining emerging opportunities in ADCs, immunotherapy, AI, and multi-omics to improve…
Germany Germany’s future competitiveness begins with the policy decisions we make today Scientific breakthroughs alone are not enough to shape the future of healthcare. They must be matched by the right policy environment, sustained investment, and a shared commitment to innovation. Daniel Steiners discusses how Roche is strengthening its position across…
Europe My message is simply to continue believing in Europe Growth creates a different set of questions. Once commercial momentum is established, the challenge shifts from building a business to sustaining innovation, preparing for scale, and ensuring that new medicines reach patients without unnecessary delay and irrespective of where they live.…
USA You cannot choose between performing and transforming. The organisations that succeed can do both As AI, shifting healthcare policy, growing pressure around affordability and access, and rapidly evolving models of commercialisation reshape the pharmaceutical industry, Deborah Glasser reflects on how Sanofi is positioning its specialty care business for the next…
USA If price is the only basis for adoption, biosimilars will not survive as a viable industry Tom Newcomer, SVP & Head of US Commercial, Samsung Bioepis, discusses the company’s evolution into a dedicated biosimilars developer with ten FDA approvals and a long-term commitment to improving affordability and access. He highlights…
See our Cookie Privacy Policy Here
